Validea Kenneth Fisher Strategy Daily Upgrade Report - 2/14/2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 14 2025
0mins
Source: NASDAQ.COM
Organon & Co. Stock Rating: The stock rating for Organon & Co. (OGN) improved from 50% to 80% based on its fundamentals and valuation, indicating significant interest according to Kenneth Fisher's investment strategy focused on low P/S ratios and strong profit growth.
Benitec Biopharma Inc. Stock Rating: Benitec Biopharma Inc. (BNTC) saw its rating increase from 40% to 70%, reflecting a positive shift in the company's underlying fundamentals and stock valuation within the biotechnology sector.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like OGN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGN is 8.50 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 8.890
Low
5.00
Averages
8.50
High
12.00
Current: 8.890
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Organon to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Organon will announce its Q4 and full year 2025 financial results on February 12, 2026, prior to a webcast and conference call, demonstrating the company's commitment to transparency.
- Milestone Expense Outlook: The company does not expect to record any milestone expenses in Q4 2025, indicating a cautious approach to cost management that supports financial stability.
- Financial Result Uncertainty: The Q4 and full year 2025 results are not yet finalized and may differ due to the quarter-end closing procedures, reflecting the company's prudence in financial reporting.
- Investor Participation Options: Interested investors can join the earnings call via specified phone numbers or the company website, enhancing engagement and communication with stakeholders.
Continue Reading
Organon to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Organon will release its Q4 and full year 2025 financial results on February 12, 2026, followed by a webcast and conference call, reflecting the company's commitment to transparency.
- Milestone Expense Expectations: The company does not anticipate recording any milestone expenses in Q4 2025, indicating a cautious approach to financial management that may influence investor confidence.
- Financial Result Uncertainty: While preliminary financial estimates have been provided, actual results are subject to the quarter-end closing procedures, highlighting potential volatility in financial outcomes that could affect market reactions.
- Investor Participation Options: Interested institutional investors and analysts can join the call by dialing specified numbers, demonstrating the company's openness and accessibility in investor communications.
Continue Reading